

Supplementary 2 The three most common sequence of regimens received by patients (n=185) in each major treatment sequence category, showing the total number of patients in each sequence category and the proportion of all treated patients (small number masking in operation).

Sequence	Agents(s)
Endo (n=51, 27.6%)	Letrozole Anastrozole Exemestane
Endo - Endo - Endo (n=19, 10.3%)	Letrozole - Exemestane – Tamoxifen Letrozole - Fulvestrant - Tamoxifen Exemestane - Tamoxifen - Letrozole
Endo - Endo (n=17, 9.2%)	Letrozole – Exemestane Letrozole – Tamoxifen Anastrozole – Exemestane
Endo - Endo - Chemo (n=8, 4.3%)	Exemestane - Fulvestrant - Capecitabine Letrozole - Exemestane - Capecitabine Anastrozole - Fulvestrant - Capecitabine
Chemo (n=7, 3.8%)	Paclitaxel EC
Endo - Endo/Targ - Endo (n=7, 3.8%)	Letrozole - Evero/Exem – Tamoxifen Letrozole - Evero/Exem - Fulvestrant Anastrozole - Evero/Exem - Fulvestrant
Chemo - Chemo (n=6, 3.2%)	Carboplatin – Capecitabine Paclitaxel – Carboplatin EC – Paclitaxel
Endo - Chemo - Chemo (n<6)	Exemestane - Capecitabine - Paclitaxel Letrozole - Paclitaxel - Capecitabine Anastrozole - Capecitabine - Paclitaxel
Endo - Endo/Targ (n<6)	Anastrozole - Evero/Exem Letrozole - Evero/Exem Tamoxifen - Evero/Exem
Chemo - Endo - Endo (n<6)	EC - Letrozole - Exemestane Capecitabine - Tamoxifen - Fulvestrant Paclitaxel - Letrozole - Anastrozole
Chemo - Endo - Chemo (n<6)	EC - Letrozole - Paclitaxel Capecitabine - Tamoxifen - Paclitaxel Carboplatin - Letrozole - Paclitaxel
Chemo - Chemo - Endo (n<6)	EC- Docetaxel - Tamoxifen Carboplatin - Paclitaxel - Anastrozole Docetaxel - Capecitabine - Fulvestrant